Syngene (established in 1993) as a Biocon subsidiary is India’s first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.
Financial Results:
Syngene International Ltd reported Revenues for Q3FY24 of ₹854.00 Crores up from ₹786.00 Crore year on year, a rise of 8.65%.
Total Expenses for Q3FY24 of ₹741.00 Crores up from ₹664.00 Crores year on year, a rise of 11.6%.
Consolidated Net Profit of ₹112.00 Crores up 1.82% from ₹110.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹2.77, up 1.47% from ₹2.73 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.